BPC-157 Research Overview:

What the Studies Show

Updated April 2026 · For research use only

Disclaimer

This blog provides independent summaries and interpretations of third-party academic research. The content is for informational purposes only and does not constitute a product claim, health claim, or medical advice.

BPC-157, formally Body Protection Compound-157, is one of the most extensively studied synthetic peptides in the preclinical literature, with over 100 published studies spanning more than three decades. First described in 1992 by Predrag Sikiric and colleagues at the University of Zagreb, it has since accumulated a substantial record in animal models and, more recently, a small number of human pilot studies. For Canadian researchers working with BPC-157 Canada suppliers, this post summarizes the publicly available molecular data, published research findings, and standard handling protocols relevant to laboratory use.

Molecular Properties

BPC-157 is a synthetic pentadecapeptide: a single, non-glycosylated polypeptide chain composed of exactly 15 amino acids. Its sequence was derived from a portion of the human gastric juice protein BPC, though this specific arrangement does not occur endogenously and was not found in the Protein BLAST database as of a 2016 analytical report. It is also referred to in the literature by the aliases PL 14736, PL-10, and Bepecin. The molecular weight of BPC-157 is approximately 1,420 Da.

Amino Acid Sequence

Gly – Glu – Pro – Pro – Pro – Gly – Lys – Pro – Ala – Asp – Asp – Ala – Gly – Leu – Val

A notable structural feature is the peptide’s high proline content: three consecutive proline residues at positions 3 through 5 confer unusual conformational rigidity and resistance to enzymatic cleavage. BPC-157 is freely soluble in water at physiological pH and demonstrates remarkable stability in human gastric juice, remaining intact for more than 24 hours. This distinguishes it from most peptides, which are rapidly degraded by stomach acid and pepsin. The compound is synthesized via solid-phase peptide synthesis (SPPS) and supplied in lyophilized white powder form.

Mechanism of Action: Key Pathways Under Investigation

Published preclinical research has identified several molecular pathways that appear to underpin BPC-157’s observed effects in animal models. These have been the subject of review articles in peer-reviewed journals including Pharmaceuticals (MDPI) and the American Journal of Sports Medicine.

FAK-Paxillin

Phosphorylation of focal adhesion kinase and paxillin, implicated in fibroblast migration and tendon cell outgrowth in ex vivo studies

GH Receptor

Enhanced growth hormone receptor expression observed in musculoskeletal tissue models, associated with upstream angiogenic signalling

eNOS / NO

Modulation of the nitric oxide pathway via endothelial nitric oxide synthase, studied in the context of vascular and cytoprotective responses

Cytokine

Reduction of pro-inflammatory cytokines in multiple preclinical injury and bowel disease models

Angiogenesis

Upregulation of VEGF and related growth factors in tissue repair models; also the basis of ongoing theoretical safety discussions regarding neovascularization

A 2025 literature and patent review published in Pharmaceuticals (MDPI) further examined BPC-157’s pleiotropic activity and proposed possible connections with neurotransmitter systems, noting its cytoprotective profile extends across gastrointestinal, musculoskeletal, and central nervous system models in animals.

Preclinical Research Landscape

The preclinical literature on BPC-157 Canada and internationally is substantial. A 2025 systematic review published in the American Journal of Sports Medicine, conducted by Vasireddi et al., identified 544 articles spanning 1993 to 2024 from PubMed, Cochrane, and Embase. After screening, 36 studies met inclusion criteria, comprising 35 preclinical studies and one clinical study, representing one of the most comprehensive syntheses of BPC-157 research to date.

544

Articles identified in the 2025 systematic review (1993–2024)

36

Studies meeting inclusion criteria after full-text screening

>100

Preclinical studies published over three decades of research

No LD50

No lethal dose identified in toxicological studies conducted in animal models

Across included preclinical studies, BPC-157 was reported to improve functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bone injury models. Investigators noted enhanced fibroblast activity, accelerated collagen remodelling, and improved vascularization at injury sites in rodent studies. Gastrointestinal models, including inflammatory bowel disease and mucosal injury, have also featured prominently in the preclinical record since the compound’s initial characterization.

Human Pilot Studies

Clinical data on BPC-157 remains limited relative to the breadth of preclinical work. As of early 2026, three small human studies have been published, collectively involving approximately 30 participants.

Clinical Study Snapshot — Lee & Padgett, 2021

A retrospective study of intra-articular BPC-157 injection for chronic knee pain (16 patients) reported that 14 of 16 participants (87.5%) experienced significant pain relief at 6 to 12 months post-injection. The study noted a small sample size, absence of a control group, and lack of unified diagnosis as key limitations.

A 2024 pilot study by Lee et al., published in Alternative Therapies in Health and Medicine, evaluated intravesicular BPC-157 injection in 12 patients with moderate to severe interstitial cystitis who had not responded to pentosan polysulfate, the only currently FDA-approved treatment for the condition. The study reported 80–100% resolution of symptoms at six weeks post-treatment, with no adverse events recorded. The authors described it as the first report of intravesicular BPC-157 administration in this indication.

A 2025 pharmacokinetic pilot study by Lee and Burgess evaluated intravenous infusion of BPC-157 in two healthy adults, administering 10 mg on day one and 20 mg on day two. No adverse effects were recorded across cardiac, hepatic, renal, thyroid, or glucose biomarkers. Plasma concentrations returned to baseline within 24 hours. Across all three published human studies, no adverse events were reported, though the authors uniformly cautioned that sample sizes are too small to draw safety conclusions at a population level.

Regulatory Context

BPC-157 is not approved for therapeutic use by any regulatory authority worldwide, including Health Canada, the FDA, or the EMA. In September 2023, the FDA classified BPC-157 as a Category 2 bulk drug substance, which effectively prohibits its inclusion in compounded medications under 503A and 503B pharmacy frameworks in the United States, citing concerns about immunogenicity, peptide-related manufacturing impurities, and insufficient human safety data. The World Anti-Doping Agency (WADA) added BPC-157 to its prohibited list in 2022 under the S0 Unapproved Substances category. It is supplied exclusively as a research compound.

Research Storage and Handling

Proper storage is essential to maintaining BPC-157 compound integrity. The peptide’s high proline content, while conferring gastric stability, makes reconstituted solutions susceptible to deamidation and isomerization at adjacent aspartic acid residues under suboptimal conditions. The following guidance reflects standard practices for this structural class:

Condition	Guidance
Lyophilized form	Store desiccated at −20°C or below, protected from light and moisture. Stable at room temperature for up to 3 weeks under dry conditions; long-term storage requires freezing.
Reconstitution vehicle	Sterile 18 MΩ·cm water or bacteriostatic water at physiological pH. Reconstitute to a minimum concentration of 100 µg/mL before further dilution.
Reconstituted solution	Store at 4°C and use within 2–7 days. For extended storage, freeze below −18°C with a carrier protein (0.1% HSA or BSA recommended).
Freeze-thaw cycles	Avoid. Isomerization and deamidation accelerate with each cycle, degrading purity even when identity is preserved by mass spectrometry.
Purity verification	Research-grade BPC-157 Canada material should carry a COA with RP-HPLC purity ≥97% and mass spectrometry confirmation of the 1,419.55 Da molecular weight.

Research-Grade BPC-157 for Canadian Researchers

Our company supplies research-grade BPC-157 for licensed researchers and institutions operating within Canada. All inventory is supported by third-party Certificate of Analysis documentation, including RP-HPLC purity verification and mass spectrometry confirmation of molecular identity at 1,419.55 Da.

Our BPC-157 orders are fulfilled strictly for in vitro and laboratory research purposes, in accordance with applicable Canadian federal regulations governing research compounds.

All compounds are supplied for research use only. This material is not intended for human or veterinary use, and no therapeutic, diagnostic, or clinical application is implied or represented.

References

Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Am J Sports Med. 2025.
Sikiric P et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals. 2024;17:461.
MDPI Pharmaceuticals: Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review. 2025.
Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8–13.
Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: A pilot study. Altern Ther Health Med. 2024;30:12–17.
Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025.